GlassScriptPhysician profile
Michael C Zlupko
NPI 1114121647
$467,858.31
in general payments reported to CMS, 2019-2025
50 companies · $114K in 2025
The $114K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $36K · 2021: $62K · 2022: $56K · 2023: $82K · 2024: $50K · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $181K · Consulting Fee: $27K · Travel and Lodging: $26K · Food and Beverage: $12K · Education: $97.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $180,581.00 |
| Consulting Fee | $27,126.00 |
| Travel and Lodging | $26,375.76 |
| Food and Beverage | $11,655.59 |
| Education | $97.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $216,658.53 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102,481.55 | 2019-2025 | Ofev, Stiolto Respimat |
| Grifols USA, LLC | $55,941.08 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Insmed, INC. | $44,750.04 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $35,507.59 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $2,361.10 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Genzyme Corporation | $2,161.68 | 2019-2025 | |
| United Therapeutics Corporation | $1,319.70 | 2020-2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $752.31 | 2019-2025 | Uptravi, Opsumit |
| Grifols Shared Services North America, INC. | $540.00 | 2023 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $460.18 | 2020-2025 | |
| Genentech USA, INC. | $421.55 | 2019-2025 | Xolair |
| Pfizer INC. | $397.60 | 2019-2021 | |
| Mylan Specialty L.P. | $336.07 | 2019-2024 | Yupelri |
| Ethicon INC. | $329.57 | 2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $328.85 | 2021-2025 | Smartvest |
| Resmed Corp | $254.15 | 2019-2025 | |
| Gilead Sciences, INC. | $252.36 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $197.70 | 2022-2024 | Acthar |
| Inspire Medical Systems, INC. | $162.30 | 2023-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $159.52 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.67 | 2020-2025 | Glassia |
| Axsome Therapeutics, INC. | $144.48 | 2025 | Sunosi |
| Sanofi-Aventis U.S. LLC | $137.98 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $128.16 | 2019-2025 | |
| Verona Pharma, INC. | $118.88 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $116.96 | 2020-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $111.15 | 2024-2025 | Lumryz |
| Advanced Respiratory, INC | $104.90 | 2019-2021 | |
| Abbvie INC. | $104.59 | 2021-2024 | Avycaz, Dalvance, Teflaro |
| Vifor Pharma, INC. | $98.01 | 2024-2025 | Zemaira |
| Amgen INC. | $95.36 | 2022-2025 | Tezspire |
| Pulmonx Corporation | $84.22 | 2019-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Zoll Respicardia, INC. | $81.42 | 2022 | |
| Paratek Pharmaceuticals, INC. | $78.32 | 2023-2024 | Nuzyra |
| Philips North America LLC | $69.25 | 2021-2024 | (Ak6) Vest Therapy |
| Merck Sharp & Dohme LLC | $66.22 | 2021-2023 | Belsomra |
| Baxter Healthcare | $61.91 | 2022-2023 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Allergan, INC. | $54.54 | 2019-2020 | |
| 3b Medical, INC. | $49.71 | 2025 | Luna |
| Teva Pharmaceuticals USA, INC. | $40.54 | 2021 | |
| Viatris Specialty LLC | $31.64 | 2025 | Yupelri |
| Circassia INC. | $28.22 | 2020 | |
| Vapotherm INC | $23.04 | 2022 | |
| Tactile Systems Technology INC | $20.71 | 2025 | Nimbl, Flexitouch Plus |
| Melinta Therapeutics, LLC | $16.92 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.82 | 2023 | Quviviq |
| Shire North American Group INC | $15.77 | 2019 | |
| Lilly USA, LLC | $14.97 | 2025 | Zepbound |
| Optinose US, INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zlupko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.